Acute Leukemia

$New Targeted Drug Approved for Certain Adults With Relapsed or Refractory AML With an NPM1 Mutation$

November 21, 2025

New Targeted Drug Approved for Certain Adults With Relapsed or Refractory AML With an NPM1 Mutation

Charles H. Weaver, MD
November 6, 2025

FDA Approves New Targeted Therapy Revuforj for Hard-to-Treat Acute Myeloid Leukemia

Charles H. Weaver, MD
November 18, 2024

FDA Approves Breakthrough Leukemia Treatment Revuforj (Revumenib)

Charles H. Weaver, MD
October 8, 2024

FDA Expands Blincyto Approval in Frontline B-Cell Precursor Acute Lymphoblastic Leukemia

Charles H. Weaver, MD
April 17, 2024

Acute Myeloid Leukemia: Overview and Treatment

Charles H. Weaver, MD
October 25, 2023

Tibsovo for Treatment of Acute Myeloid Leukemia

Charles H. Weaver, MD
March 22, 2023

Revumenib Shows Promise in Acute Leukemia

Charles H. Weaver, MD
October 29, 2022

FDA Approves Pemazyre for Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement

Charles H. Weaver, MD
March 30, 2022

Pemazyre for FGFR1-Mutant Myeloid, Lymphoid Neoplasms

Charles H. Weaver, MD
March 3, 2021

Blincyto Prolongs Survival in Acute Lymphoblastic Leukemia (ALL)

Charles H. Weaver, MD
January 12, 2021

Vidaza Provide Alternative Treatment for Transplant Ineligble AML

Charles H. Weaver, MD
September 1, 2020

Venclexta® for Acute Myeloid Leukemia

Charles H. Weaver, MD